Cargando…
Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population
BACKGROUND: The relationship of glucosamine use with incident dementia in the older population remains uncertain. We aimed to evaluate the longitudinal association between habitual glucosamine supplement and the risk of cause-specific dementia and examine the possible effect modifiers on this associ...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492372/ https://www.ncbi.nlm.nih.gov/pubmed/37689747 http://dx.doi.org/10.1186/s13195-023-01295-6 |
_version_ | 1785104241777442816 |
---|---|
author | Zhou, Chun Zhang, Yanjun Yang, Sisi Ye, Ziliang Wu, Qimeng Liu, Mengyi He, Panpan Zhang, Yuanyuan Qin, Xianhui |
author_facet | Zhou, Chun Zhang, Yanjun Yang, Sisi Ye, Ziliang Wu, Qimeng Liu, Mengyi He, Panpan Zhang, Yuanyuan Qin, Xianhui |
author_sort | Zhou, Chun |
collection | PubMed |
description | BACKGROUND: The relationship of glucosamine use with incident dementia in the older population remains uncertain. We aimed to evaluate the longitudinal association between habitual glucosamine supplement and the risk of cause-specific dementia and examine the possible effect modifiers on this association. METHODS: The study included 214,945 participants over the age of 60 who had available information on glucosamine use and did not have dementia at baseline in the UK Biobank. The APOE genotypes were determined by a combination variant of rs429358 and rs7412. The primary outcome was incident vascular dementia, incident Alzheimer’s disease, and incident frontotemporal dementia, respectively. RESULTS: Over a median follow-up duration of 12 years, 1039, 1774, and 122 participants developed vascular dementia, Alzheimer’s disease, and frontotemporal dementia, respectively. Overall, habitual glucosamine use was significantly associated with a lower risk of incident vascular dementia (adjusted HR, 0.82; 95%CI, 0.70–0.96), but not significantly associated with incident Alzheimer’s disease (adjusted HR, 1.02; 95%CI, 0.92–1.14) and incident frontotemporal dementia (adjusted HR, 0.95; 95%CI, 0.63–1.43). Moreover, the inverse association between habitual glucosamine use and incident vascular dementia was more pronounced in participants with concomitant supplement of calcium (P-interaction = 0.011), and those without concomitant supplement of zinc (P-interaction = 0.018). However, APOE ε4 dosage and baseline cognitive function did not significantly modify the relationships of glucosamine use with incident vascular dementia or Alzheimer’s disease (All P-interactions > 0.05). CONCLUSIONS: Regardless of APOE genotypes and baseline cognitive function, habitual glucosamine use was significantly inversely associated with incident vascular dementia in the older population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01295-6. |
format | Online Article Text |
id | pubmed-10492372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104923722023-09-10 Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population Zhou, Chun Zhang, Yanjun Yang, Sisi Ye, Ziliang Wu, Qimeng Liu, Mengyi He, Panpan Zhang, Yuanyuan Qin, Xianhui Alzheimers Res Ther Research BACKGROUND: The relationship of glucosamine use with incident dementia in the older population remains uncertain. We aimed to evaluate the longitudinal association between habitual glucosamine supplement and the risk of cause-specific dementia and examine the possible effect modifiers on this association. METHODS: The study included 214,945 participants over the age of 60 who had available information on glucosamine use and did not have dementia at baseline in the UK Biobank. The APOE genotypes were determined by a combination variant of rs429358 and rs7412. The primary outcome was incident vascular dementia, incident Alzheimer’s disease, and incident frontotemporal dementia, respectively. RESULTS: Over a median follow-up duration of 12 years, 1039, 1774, and 122 participants developed vascular dementia, Alzheimer’s disease, and frontotemporal dementia, respectively. Overall, habitual glucosamine use was significantly associated with a lower risk of incident vascular dementia (adjusted HR, 0.82; 95%CI, 0.70–0.96), but not significantly associated with incident Alzheimer’s disease (adjusted HR, 1.02; 95%CI, 0.92–1.14) and incident frontotemporal dementia (adjusted HR, 0.95; 95%CI, 0.63–1.43). Moreover, the inverse association between habitual glucosamine use and incident vascular dementia was more pronounced in participants with concomitant supplement of calcium (P-interaction = 0.011), and those without concomitant supplement of zinc (P-interaction = 0.018). However, APOE ε4 dosage and baseline cognitive function did not significantly modify the relationships of glucosamine use with incident vascular dementia or Alzheimer’s disease (All P-interactions > 0.05). CONCLUSIONS: Regardless of APOE genotypes and baseline cognitive function, habitual glucosamine use was significantly inversely associated with incident vascular dementia in the older population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01295-6. BioMed Central 2023-09-09 /pmc/articles/PMC10492372/ /pubmed/37689747 http://dx.doi.org/10.1186/s13195-023-01295-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zhou, Chun Zhang, Yanjun Yang, Sisi Ye, Ziliang Wu, Qimeng Liu, Mengyi He, Panpan Zhang, Yuanyuan Qin, Xianhui Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population |
title | Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population |
title_full | Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population |
title_fullStr | Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population |
title_full_unstemmed | Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population |
title_short | Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population |
title_sort | habitual glucosamine use, apoe genotypes, and risk of incident cause-specific dementia in the older population |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492372/ https://www.ncbi.nlm.nih.gov/pubmed/37689747 http://dx.doi.org/10.1186/s13195-023-01295-6 |
work_keys_str_mv | AT zhouchun habitualglucosamineuseapoegenotypesandriskofincidentcausespecificdementiaintheolderpopulation AT zhangyanjun habitualglucosamineuseapoegenotypesandriskofincidentcausespecificdementiaintheolderpopulation AT yangsisi habitualglucosamineuseapoegenotypesandriskofincidentcausespecificdementiaintheolderpopulation AT yeziliang habitualglucosamineuseapoegenotypesandriskofincidentcausespecificdementiaintheolderpopulation AT wuqimeng habitualglucosamineuseapoegenotypesandriskofincidentcausespecificdementiaintheolderpopulation AT liumengyi habitualglucosamineuseapoegenotypesandriskofincidentcausespecificdementiaintheolderpopulation AT hepanpan habitualglucosamineuseapoegenotypesandriskofincidentcausespecificdementiaintheolderpopulation AT zhangyuanyuan habitualglucosamineuseapoegenotypesandriskofincidentcausespecificdementiaintheolderpopulation AT qinxianhui habitualglucosamineuseapoegenotypesandriskofincidentcausespecificdementiaintheolderpopulation |